13F Holdings
中文EN

TIL Instil Bio, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1789769 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY71.9%
TTM EPS YoY73.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-19.2%
ROA-10.4%
ROIC (approx.)-21.8%
Asset turnover—

Leverage & solvency

Liabilities / assets47.6%
Debt / equity0.00x
Current ratio10.42x
Interest coverage-4.69x

Cash quality & payout

Operating cash flow / net income0.73x
Accruals ratio-2.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue————$0
R&D expense$24.74M$11.84M$39.60M$141.06M$107.25M
SG&A expense$27.22M$44.21M$47.55M$62.23M$48.31M
Operating income-$78.58M-$73.54M-$159.17M-$226.46M-$155.56M
Interest expense$5.83M$8.99M$5.21M$1.88M$0
Pretax income-$71.37M-$74.14M-$156.09M-$225.25M-$156.75M
Income tax$0—$0-$2.07M$39,000
Net income-$71.37M-$74.14M-$156.09M-$223.18M-$156.79M
EBITDA-$78.05M-$69.93M-$154.41M-$220.47M-$152.81M
EPS (basic)-10.70-11.39-24.00-34.46-1.48
EPS (diluted)-10.70-11.39-24.00-34.46-1.48
Weighted avg. shares (diluted)6.67M6.51M6.50M6.48M105.99M
Balance sheet
Cash & equivalents$6.64M$10.63M$10.70M$43.72M$38.09M
Short-term investments$69.49M—$141.16M$217.20M$416.51M
Current assets$192.42M$124.47M$160.76M$269.38M$464.02M
PP&E, net$126,000$129.41M$138.68M$196.88M$122.00M
Goodwill———$0$5.72M
Total assets$204.51M$263.57M$325.63M$482.13M$609.98M
Current liabilities$7.03M$7.90M$10.56M$32.79M$41.36M
Total liabilities$91.84M$94.13M$99.80M$118.52M$54.78M
Shareholders' equity$112.67M$168.27M$225.83M$363.61M$555.20M
Shares outstanding6.78M6.53M6.50M6.50M129.03M
Cash flow statement
Operating cash flow-$36.62M-$55.70M-$82.03M-$180.16M-$122.14M
Capital expenditure—$0$20.66M$84.59M$57.83M
Free cash flow—-$55.70M-$102.69M-$264.75M-$179.97M
Investing cash flow$25.48M$53.97M$41.13M$114.54M-$474.40M
Financing cash flow$7.29M$1.75M$8.08M$71.89M$393.16M
Depreciation & amortization$534,000$3.61M$4.76M$5.99M$2.75M
Stock-based compensation$8.69M$17.26M$18.17M$30.44M$26.20M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.